Also, PT2385 treatment reduced the expression of genes regulated by HIF2α in AML cells (FLT3, CDK6, BCL11A, RUNX2, UHRF1, and TRIM28), thus confirming a block of HIF2α activity (Figs 4C and EV3D). The gene discussed is BCL11A; the disease is acute myeloid leukemia.